Endo International PLC (NASDAQ:ENDP) (TSE:ENL)‘s stock had its “hold” rating reiterated by equities researchers at Piper Jaffray Companies in a report released on Sunday. They currently have a $9.00 target price on the stock. Piper Jaffray Companies’ price target would indicate a potential upside of 4.65% from the company’s current price.

ENDP has been the topic of a number of other reports. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a research report on Sunday, July 23rd. Mizuho restated a “buy” rating and set a $14.00 price target (down from $19.00) on shares of Endo International PLC in a research report on Tuesday, September 12th. William Blair restated a “market perform” rating on shares of Endo International PLC in a research report on Wednesday, June 14th. Zacks Investment Research downgraded shares of Endo International PLC from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the stock a “hold” rating in a research report on Monday, May 22nd. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the stock. Endo International PLC has an average rating of “Hold” and an average price target of $14.33.

Shares of Endo International PLC (NASDAQ ENDP) opened at 8.60 on Friday. Endo International PLC has a one year low of $7.41 and a one year high of $23.98. The stock has a 50 day moving average of $8.88 and a 200-day moving average of $10.89. The stock’s market capitalization is $1.92 billion.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. Endo International PLC’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $0.86 EPS. Equities analysts predict that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Reaffirms “Hold” Rating for Endo International PLC (ENDP)” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/17/piper-jaffray-companies-reaffirms-hold-rating-for-endo-international-plc-endp.html.

In other news, CFO Blaise Coleman bought 6,500 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were acquired at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at approximately $108,321.81. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was purchased at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. Over the last three months, insiders bought 36,000 shares of company stock worth $279,460. 0.50% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Gamco Investors INC. ET AL increased its position in shares of Endo International PLC by 5.6% in the second quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company’s stock worth $700,000 after acquiring an additional 3,300 shares in the last quarter. James Investment Research Inc. purchased a new position in shares of Endo International PLC in the second quarter worth approximately $113,000. Russell Investments Group Ltd. increased its position in shares of Endo International PLC by 20.9% in the second quarter. Russell Investments Group Ltd. now owns 325,860 shares of the company’s stock worth $3,640,000 after acquiring an additional 56,407 shares in the last quarter. OppenheimerFunds Inc. increased its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after acquiring an additional 1,857,678 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after acquiring an additional 483,545 shares in the last quarter. 90.74% of the stock is currently owned by institutional investors and hedge funds.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.